KRYSTEXXA® (pegloticase) | Uncontrolled Gout Treatment
Release your everyday from gout with KRYSTEXXA, a treatment that lowers uric acid and can dissolve years of gout buildup in months, according to studies. Call a Gout Nurse Advocate for help at 1-833-469-4688
A Different Kind of Uric Acid Treatment - KRYSTEXXA
KRYSTEXXA is the only gout treatment that controls chronic gout by changing uric acid into a water-soluble substance called allantoin that your body easily gets rid of through urine. Significantly lower your uric acid level in 24 hours
FDA Approves Canakinumab to Treat Gout Flares
2023年11月3日 · On Aug. 25, the U.S. Food & Drug Administration (FDA) approved canakinumab (Ilaris) for the treatment of gout flares in adult patients who can’t tolerate non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine, or for whom NSAIDs and colchicine are contraindicated or provide an inadequate response.
FDA approves Ilaris for the treatment of gout flares in adults
2023年8月31日 · The FDA has approved Ilaris for the treatment of gout flares in adults, marking it as the first biologic therapy to receive the nod for this indication, according to a statement from...
List of 9 Gout Medications Compared - Drugs.com
Medicines used to treat gout attacks relieve pain and inflammation and include: Nonsteroidal anti-inflammatory drugs (NSAIDs) colchicine; Corticosteroids. Medicines to prevent recurrences of gout either block the production of uric acid or improve its removal. Examples include: allopurinol; febuxostat; pegloticase; probenecid.
FDA Roundup: Pipeline Drugs for Gout - Rheumatology Advisor
2024年2月9日 · These emerging interventions not only target the acute symptoms of gout but also aim to address the underlying cause — hyperuricemia — with the goal of achieving lasting reductions in serum urate levels. 1 From advanced xanthine oxidase inhibitors to groundbreaking strategies in specific NOD-like receptor family, pyrin domain-containing 3 protei...
Novel Gout Drug Passes Mid-Stage Test - Medpage Today
2023年1月20日 · An investigational non-purine xanthine oxidase inhibitor for gout treatment, called tigulixostat, appeared effective enough in a phase II trial that a pivotal study is now getting underway.
Emerging therapeutic options for refractory gout - Nature
2023年12月15日 · For individuals with gout, the treatment options beyond conventional urate-lowering therapies are expanding. Notable advancements in 2023 include developments in uricase therapy, new xanthine...
New drug targets for the treatment of gout arthritis: what's new?
In this sense, we envisage four possibilities for GA therapeutics, which include the repurposing of existing therapies, ALX/FPR2 agonism for improvement in disease outcome, the use of multitarget drugs (e.g. natural products), and targeting the neuroinflammatory component of GA.
Krystexxa Chronic Gout Medication Gets Expanded FDA Approval
2022年7月14日 · Rare and rheumatic disease-focused biotech Horizon Therapeutics has received expanded approval from the US Food and Drug Administration (FDA) for its gout injection Krystexxa (pegloticase) to include its co-administration with the immunomodulator methotrexate.